PacBio Q4 revenue rises 14% driven by strong consumable sales

Reuters

02/13

PacBio Q4 revenue rises 14% driven by strong consumable sales

Overview

Life science tech firm's Q4 revenue rose 14% yr/yr, driven by record consumable sales
Adjusted net income for Q4 beat analyst expectations
Company completed sale of short-read sequencing assets, strengthening balance sheet

Outlook

Company plans to launch SPRQ-Nx to lower sequencing costs in 2026
PacBio aims to drive growth with strengthened balance sheet post asset sale
Company did not provide specific financial guidance for 2026

Result Drivers

RECORD CONSUMABLE SALES - Consumable revenue reached an all-time high, contributing significantly to Q4 revenue growth
ASSET SALE - Completed sale of short-read sequencing assets, strengthening balance sheet
DECLINE IN REVIO PLACEMENTS - Revio system placements decreased compared to the previous year

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Adjusted Net Income	Beat	-$37.60 mln	-$44.30 mln (4 Analysts)
Q4 Adjusted Gross Profit		$17.80 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00, about 8.7% above its February 11 closing price of $1.84

Press Release: ID:nGNX8cG9QQ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2611557908"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611557908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611557908?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 05:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611557908","market":"nz","top_or_hot":-1,"title":"PacBio Q4 revenue rises 14% driven by strong consumable sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>PacBio Q4 revenue rises 14% driven by strong consumable sales</title></head><body><p><span>Overview</span></p><ul><li><p>Life science tech firm's Q4 revenue rose 14% yr/yr, driven by record consumable sales</p></li><li><p>Adjusted net income for Q4 beat analyst expectations</p></li><li><p>Company completed sale of short-read sequencing assets, strengthening balance sheet</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to launch SPRQ-Nx to lower sequencing costs in 2026</p></li><li><p>PacBio aims to drive growth with strengthened balance sheet post asset sale</p></li><li><p>Company did not provide specific financial guidance for 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>RECORD CONSUMABLE SALES - Consumable revenue reached an all-time high, contributing significantly to Q4 revenue growth</p></li><li><p>ASSET SALE - Completed sale of short-read sequencing assets, strengthening balance sheet</p></li><li><p>DECLINE IN REVIO PLACEMENTS - Revio system placements decreased compared to the previous year</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$37.60 mln</p></td><td><p>-$44.30 mln (4 Analysts)</p></td></tr><tr><td><p>Q4 Adjusted Gross Profit</p></td><td></td><td><p>$17.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 6 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00, about 8.7% above its February 11 closing price of $1.84</p></li></ul><p>Press Release: <span>ID:nGNX8cG9QQ</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PacBio Q4 revenue rises 14% driven by strong consumable sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacBio Q4 revenue rises 14% driven by strong consumable sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-13 05:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>PacBio Q4 revenue rises 14% driven by strong consumable sales</title></head><body><p><span>Overview</span></p><ul><li><p>Life science tech firm's Q4 revenue rose 14% yr/yr, driven by record consumable sales</p></li><li><p>Adjusted net income for Q4 beat analyst expectations</p></li><li><p>Company completed sale of short-read sequencing assets, strengthening balance sheet</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company plans to launch SPRQ-Nx to lower sequencing costs in 2026</p></li><li><p>PacBio aims to drive growth with strengthened balance sheet post asset sale</p></li><li><p>Company did not provide specific financial guidance for 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>RECORD CONSUMABLE SALES - Consumable revenue reached an all-time high, contributing significantly to Q4 revenue growth</p></li><li><p>ASSET SALE - Completed sale of short-read sequencing assets, strengthening balance sheet</p></li><li><p>DECLINE IN REVIO PLACEMENTS - Revio system placements decreased compared to the previous year</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$37.60 mln</p></td><td><p>-$44.30 mln (4 Analysts)</p></td></tr><tr><td><p>Q4 Adjusted Gross Profit</p></td><td></td><td><p>$17.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 6 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00, about 8.7% above its February 11 closing price of $1.84</p></li></ul><p>Press Release: <span>ID:nGNX8cG9QQ</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4567","symbol_name":"ESG概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL1N3Z81GE:1","article_id":"2611557908","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611557908","pubTimestamp":1770931652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PacBio Q4 revenue rises 14% driven by strong consumable salesOverviewLife science tech firm's Q4 revenue rose 14% yr/yr, driven by record consumable salesAdjusted net income for Q4 beat analyst expect","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4567":"ESG概念","BK4149":"建筑机械与重型卡车","CMI":"康明斯","BK4585":"ETF&股票定投概念","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4121":"生命科学工具和服务","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","PACB":"Pacific Biosciences of Californi","BK4588":"碎股"},"translate_title":"受耗材销售强劲推动，PacBio第四季度收入增长14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMI":0.9,"PACB":0.9},"content_text":"PacBio Q4 revenue rises 14% driven by strong consumable salesOverviewLife science tech firm's Q4 revenue rose 14% yr/yr, driven by record consumable salesAdjusted net income for Q4 beat analyst expectationsCompany completed sale of short-read sequencing assets, strengthening balance sheetOutlookCompany plans to launch SPRQ-Nx to lower sequencing costs in 2026PacBio aims to drive growth with strengthened balance sheet post asset saleCompany did not provide specific financial guidance for 2026Result DriversRECORD CONSUMABLE SALES - Consumable revenue reached an all-time high, contributing significantly to Q4 revenue growthASSET SALE - Completed sale of short-read sequencing assets, strengthening balance sheetDECLINE IN REVIO PLACEMENTS - Revio system placements decreased compared to the previous yearKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Adjusted Net IncomeBeat-$37.60 mln-$44.30 mln (4 Analysts)Q4 Adjusted Gross Profit$17.80 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", 6 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy.\"Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.00, about 8.7% above its February 11 closing price of $1.84Press Release: ID:nGNX8cG9QQFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}